MARKET

APVO

APVO

Aptevo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.69
-0.72
-8.56%
After Hours: 7.69 0 0.00% 17:00 07/10 EDT
OPEN
8.53
PREV CLOSE
8.41
HIGH
8.87
LOW
7.66
VOLUME
436.83K
TURNOVER
--
52 WEEK HIGH
14.28
52 WEEK LOW
2.944
MARKET CAP
24.86M
P/E (TTM)
-0.7705
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average APVO stock price target is 32.33 with a high estimate of 42.00 and a low estimate of 24.00.

EPS

APVO News

More
All You Need to Know About Aptevo Therapeutics Inc. (APVO) Rating Upgrade to Buy
Zacks · 06/30 17:00
Has Aptevo Therapeutics (APVO) Outpaced Other Medical Stocks This Year?
Zacks · 06/30 16:30
Aptevo Therapeutics collects $0.75M working capital escrow
Seeking Alpha - Article · 06/29 13:51
Aptevo collects $750K payment from sale of hemophilia therapy
Seeking Alpha - Article · 06/29 13:51
Aptevo rallies on royalty stream from rituximab biosimilar
Seeking Alpha - Article · 06/25 19:27
Aptevo rises sharply after royalty payment from Pfizer
Seeking Alpha - Article · 06/25 14:01
Aptevo Therapeutics To Receive Seven Year Quarterly Royalty Payment Stream From Pfizer For Sales Of Rituximab Biosimilar
Aptevo Therapeutics to receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimilar Published Articles Suggest the Global Market for Rituximab Biosimilars Could Potentially be
Benzinga · 06/25 13:06
78 Biggest Movers From Yesterday
Gainers
Benzinga · 05/12 09:02

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About APVO

Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company's investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company's marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)) and VARIZIG (Varicella Zoster Immune Globulin (Human)).
More

Webull offers kinds of Aptevo Therapeutics Inc stock information, including NASDAQ:APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.